Acrongenomics partner Molecular Vision successful in winning prestigious award from the UK Royal Society.
April 17, 2007
Geneva, Switzerland--Acrongenomics,Inc. (OTCBB:AGNM) announces that its partner Molecular Vision has been successful in winning the £250,000 Royal Society Brian Mercer Award for Innovation 2007. This is a prestigious award from the UK’s Royal Society to develop low-cost, high throughput, reel to reel, manufacturing techniques for plastic electronics.
Acrongenomics and Molecular Vision`s medical diagnostic products use organic semiconductors to generate and detect light. This is the highly sophisticated technology used in the chemiluminescence and fluorescence demonstrators presented to a selective technical audience recently. This award has the potential of significantly driving down the cost of these devices so enabling medical point-of-care technology to be brought to the global market."
“Awards of this magnitude give additional recognition to our scientific work, establishing the great potential of our technology to change the way we live, and make a great contribution to the global medical community” said Plato Tzouvalis President of Acrongenomics
About the UK Royal Society
The Royal Society is the world's oldest scientific academy in continuous existence, and has been at the forefront of enquiry and discovery since its foundation in 1660.
The backbone of the Society is its Fellowship of the most eminent scientists of the day, elected by peer review for life and entitled to use FRS after their name. There are currently more than 60 Nobel Laureates amongst the Society's approximately 1400 Fellows and Foreign Members.
Throughout its history, the Society has promoted excellence in science through its Fellowship and Foreign Membership, which has included Isaac Newton, Charles Darwin, Ernest Rutherford, Albert Einstein, Dorothy Hodgkin, Francis Crick, James Watson and Stephen Hawking. The Society is independent of government, as it has been throughout its existence, by virtue of its Royal Charters. In 1663, The Royal Society of London for the Improvement of Natural Knowledge was granted its Arms and adopted the motto "Nullius in verba", an expression of its enduring commitment to empirical evidence as the basis of knowledge about the natural world.
About Molecular Vision Ltd
Molecular Vision is a spin-out company of Imperial Innovations Ltd. The company was founded by three Imperial College London researchers -- Prof. Donal Bradley, Prof. Andrew de Mello and Dr. John de Mello -- in 2002 in order to meet a clearly defined demand in the medical diagnostics, biosensors and analytical instrumentations markets: the need for miniaturized chemical and biological detectors offering high sensitivity and functionality at low cost. The company has directly addressed this market demand by inventing a novel method for optical detection based on recent advances in organic electronics and light emitting diodes combined with microfluidics technology. The company has mainly focused on applying its technology to the medical diagnostics markets. Molecular Vision recently signed a major development contract with Acrongenomics Inc. to jointly exploit and commercialize the technology.
About Acrongenomics Inc.
Acrongenomics Inc. is a publicly traded company that focuses on investing in and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-orientated applications.
Important Information About Forward-Looking Statements
All statements in this news release that are other than statements of historical facts are forward-looking statements which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates", "believes", "could", "expects", "intends", "may", "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions. For further information concerning risks and uncertainties that may affect our future results, please review the disclosures contained in our latest filings with the SEC, including our most recent annual report on Form 10-KSB, and subsequent quarterly reports on Form 10-QSB. Other than as required by federal securities laws, we undertake no obligation to publicly update or revise any of our forward-looking statements, whether as a result of changed circumstances, new information, future events, or for any other reason occurring after the date of this news release.
